ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0832

Cumulative Social Disadvantage Is Associated with Disease Activity and Functional Disability in Juvenile Idiopathic Arthritis: An Analysis of the CARRA Registry

William Soulsby, Erica Lawson, John Boscardin and Emily von scheven, University of California San Francisco, San Francisco, CA

Meeting: ACR Convergence 2023

Keywords: Disease Activity, Disparities, Juvenile idiopathic arthritis, Pediatric rheumatology, socioeconomic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: Abstracts: Pediatric Rheumatology – Clinical I: JIA

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: The impact of race and social determinants of health (SDoH) on health outcomes in juvenile idiopathic arthritis (JIA) remains poorly understood. Prior disparities research in JIA has largely analyzed these complex, intertwined social variables as independent risk factors and have reported inconsistent results of their impact on clinical outcomes, such as joint damage, pain, and disability. These inconsistencies may result from a failure to investigate interrelationships between social variables. A recent analysis demonstrated an association between cumulative social disadvantage and childhood arthritis using a combined score. In this analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, we used a similar method to investigate the effect of cumulative social disadvantage on disease activity and functional disability in JIA.

Methods: This is a cohort study of subjects with JIA enrolled in the CARRA Registry between July 2015-January 2022 with at least one Registry visit including all components of the clinical Juvenile Arthritis Disease Activity Score (cJADAS) and Child Health Assessment Questionnaire (CHAQ) score. A cumulative social disadvantage score was created, with a score of 1 given for each of the following: income (household income < $50,000/year), guardian education (high school or less), insurance (public insurance or none), and non-White race. Any missing components were given a score of 0.Univariate and multivariable logistic regression models, adjusted for age at enrollment, sex, JIA category, and any use of a conventional (cs-), biologic (bs-) DMARD, or small molecule, were used to estimate the odds of persistent disease activity (oligoarticular JIA – cJADAS ≥1.1; all other categories >2.5) and functional disability (CHAQ score > 0).Random effect was included in the regression models to account for repeated measures.

Results: 9,672 subjects with JIA were identified (Table 1).Oligoarticular and RF- polyarticular JIA were the most common JIA subtypes reported. The majority of cohort required DMARD treatment (68.7%).48.9% of the cohort had exposure to at least one variable associated with the combined score.47.9% of patients were classified as having high cJADAS, and 56.8% had a high CHAQ score. In both unadjusted and adjusted analysis, cumulative social disadvantage with higher odds of active disease, highest for a score of 3 (Table 2 – adjusted odds ratio [aOR] 2.31, 95% CI: 1.97-2.71), and functional disability, also highest for a score of 3 (Table 3 – aOR 3.94, 95% CI: 3.15-4.93).

Conclusion: Cumulative social disadvantage was associated with higher odds of active disease and functional disability compared to those not experiencing these exposures among JIA subjects in the CARRA Registry. Exposure to multiple variables associated with social disadvantage confers higher risk of poor outcomes in JIA. To mitigate these disparities, targeted social risk screening adopted within pediatric rheumatology clinics should be studied as a potential intervention to identify at-risk patients who may benefit from social network support or other programming, such as patient navigation services.

Supporting image 1

Table 1: Demographic and clinical characteristics of pediatric patients with juvenile idiopathic arthritis (JIA) in the CARRA Registry.

Supporting image 2

Table 2: Mixed effects model to estimate the effect of cumulative social disadvantage on persistent disease activity in children with JIA in the CARRA Registry

Supporting image 3

Table 3: Mixed effects model to estimate the effect of cumulative social disadvantage on persistent functional disability in children with JIA in the CARRA Registry


Disclosures: W. Soulsby: None; E. Lawson: Pfizer, 5; J. Boscardin: None; E. von scheven: None.

To cite this abstract in AMA style:

Soulsby W, Lawson E, Boscardin J, von scheven E. Cumulative Social Disadvantage Is Associated with Disease Activity and Functional Disability in Juvenile Idiopathic Arthritis: An Analysis of the CARRA Registry [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/cumulative-social-disadvantage-is-associated-with-disease-activity-and-functional-disability-in-juvenile-idiopathic-arthritis-an-analysis-of-the-carra-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cumulative-social-disadvantage-is-associated-with-disease-activity-and-functional-disability-in-juvenile-idiopathic-arthritis-an-analysis-of-the-carra-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology